CD99 and acute myeloid leukemia: Similarly, in USC100, obtained from a patient with refractory/relapsed FLT3-ITD AML, this sample showed a significant decrease in the number of cells at 72 hours in all three treatment groups compared with A192-treated group (FLT3-A192 vs. A192, P = 0.0008, 34% decrease; CD99-A192 vs. A192, P = 0.03, 24% decrease; Co-Assembled vs. A192, P < 0.0001, 49% decrease) as well as between CD99-A192 and Co-Assembled (Co-Assembled vs. CD99-A192, P < 0.009, 36% decrease; Fig. 4J).